VTRO (Vitro Biopharma) Revenue: $3.29 Mil (TTM As of Oct. 2022)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Vitro Biopharma Revenue?

Vitro Biopharma VTRO Revenue is $3.29 Mil as of Oct. 2022. The stock has 6 warning signs investors should review.

Vitro Biopharma's revenue for the three months ended in Oct. 2022 was $3.29 Mil. Its revenue for the trailing twelve months (TTM) ended in Oct. 2022 was $3.29 Mil. Vitro Biopharma's Revenue per Share for the three months ended in Oct. 2022 was $0.03. Its Revenue per Share for the trailing twelve months (TTM) ended in Oct. 2022 was $0.03.

During the past 12 months, the average Revenue per Share Growth Rate of Vitro Biopharma was 153.10% per year. During the past 3 years, the average Revenue per Share Growth Rate was 218.80% per year. During the past 5 years, the average Revenue per Share Growth Rate was 132.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.

During the past 13 years, Vitro Biopharma's highest 3-Year average Revenue per Share Growth Rate was 218.80% per year. The lowest was 26.00% per year. And the median was 88.95% per year.

Vitro Biopharma  (AMEX:VTRO) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.

Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.

Vitro Biopharma Revenue Related Terms

Vitro Biopharma Revenue Historical Data

* Premium members only.

The historical data trend for Vitro Biopharma's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vitro Biopharma Revenue Chart

Vitro Biopharma Annual Data
Trend Oct09 Oct10 Oct11 Oct12 Oct13 Oct14 Oct15 Oct17 Oct21 Oct22
Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.14 0.10 0.26 1.31 3.29

Vitro Biopharma Quarterly Data
Oct00 Oct01 Oct02 Oct03 Oct04 Oct05 Oct06 Oct07 Oct08 Oct09 Oct10 Oct11 Oct12 Oct13 Oct14 Oct15 Oct17 Oct21 Oct22
Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.14 0.10 0.26 1.31 3.29

VTRO vs : Revenue Comparison

For the Biotechnology subindustry, Vitro Biopharma's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vitro Biopharma Revenue vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vitro Biopharma's Revenue distribution charts can be found below:

* The bar in red indicates where Vitro Biopharma's Revenue falls into.


Vitro Biopharma Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Oct. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.29 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Revenue →
What does a Revenue of $3.29 Mil mean?
Vitro Biopharma (VTRO) has a Revenue of $3.29 Mil as of Oct. 2022. Revenue is the total amount a company generates as sales through its operations. View historical data on Vitro Biopharma and its competitors.
Is Vitro Biopharma's Revenue too high?
Vitro Biopharma's current Revenue is $3.29 Mil.
How does Vitro Biopharma's Revenue compare to ?
Vitro Biopharma's Revenue of $3.29 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Biotechnology company?
A good Revenue depends on the Biotechnology industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Vitro Biopharma and its competitors. Vitro Biopharma's current Revenue is $3.29 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vitro Biopharma stock overvalued right now?
Vitro Biopharma (VTRO) has a current Revenue of $3.29 Mil. The current Revenue is $3.29 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Vitro Biopharma (VTRO), the current Revenue is $3.29 Mil as of Oct. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Vitro Biopharma Business Description

Comparable Companies
Address 4621 Technology Drive, Golden, CO, USA, 80403
Vitro Diagnostics Inc is a US-based company, which is dedicated to providing high-quality commercialized cell lines, media, and stem cell technology for applications in stem cell research, drug discovery, and therapies. In addition, it also provides tools for clinical development focused on Mesenchymal Stem Cells (MSCs). Further, it offers cancer-associated fibroblasts (CAFs), which are used in the discovery of a new type of CAFs present in pancreatic cancer tumors, called pancreatic stellate cells. Geographically business activities are functioned through the region of United States.